NCT04905017招募中不适用
Early Feasibility Study of the Trisol System
Trisol Medical14 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2022年3月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 14
- 主要终点
- Rate of procedural success
研究概览
简要总结
The objective of this early feasibility study is to gain early clinical insight into Trisol system safety and performance to treat patients with moderate or greater tricuspid regurgitation (TR).
详细描述
A prospective, single-arm, open-label, multi-center early feasibility clinical study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >18 years.
- •Subject meets the legal minimum age to provide informed consent based on local regulatory requirements.
- •Participant has symptomatic, moderate or greater functional or degenerative tricuspid regurgitation (TR) as determined by the Echocardiography Core Lab assessment of a qualifying transthoracic echocardiogram (TTE) and/or transesophageal echocardiogram (TEE).
- •New York Heart Association (NYHA) Functional Class II to IVa.
- •Participant is deemed at high surgical risk or greater for tricuspid valve surgery and appropriate for transcatheter tricuspid valve replacement as determined by the local Heart Team.
- •Participant adequately treated based upon medical standards, including for coronary artery disease, mitral regurgitation, and Guideline-Directed Medical Therapy (GDMT) for heart failure for at least 30-days prior to index procedure.
- •Male or non-pregnant female.
- •Participant understands the nature of the procedure and provides written informed consent prior to any study specific assessments.
- •Participant is willing and able to comply with the specified study requirements and follow-up evaluations.
- •Participant is anatomically suitable for the Trisol system, including trans-jugular access as per imaging requirements, and is approved by the Subject Screening Committee
排除标准
- •Previous tricuspid valve repair or replacement which may impede proper study device delivery or deployment.
- •Stroke or transient ischemic event within the previous 90 days.
- •Acute myocardial infarction within the previous 90 days.
- •Hemodynamic instability requiring inotropic therapy or mechanical hemodynamic support devices.
- •Untreated clinically significant coronary artery disease requiring revascularization.
- •Implant or revision of any rhythm management device (CRT or CRT-D) or implantable cardioverter-defibrillator within the previous 30 days.
- •New or untreated right heart chamber or/and superior vena cava intracardiac mass, thrombus, or vegetation.
- •Systolic pulmonary arterial pressure (sPAP) > 80 mmHg as measured by pulmonary pressure catheter.
- •Severe RV dysfunction with RV Stroke Work Index (RVSWI) g/m2/beat <400 and Pulmonary Artery Pulsatile index (PAPi) <
- •Ongoing sepsis, including active endocarditis.
- •Active infection requiring current antibiotic therapy.
- •Known bleeding diathesis or hypercoagulable state.
- •Blood dyscrasias as defined: leukopenia (WBC <3000 cells/mm3), thrombocytopenia (platelet count <50,000 cells/mm3).
- •Active gastrointestinal (GI) bleeding or history of GI bleed within the previous 60 days that would preclude anticoagulation.
- •LVEF <25% as measured by resting echocardiogram within 30 days prior to index procedure.
- •Patients in whom transesophageal echocardiography is contraindicated.
- •Aortic, mitral or pulmonary valve disease (severe stenosis or severe regurgitation) requiring intervention or performed within 90 days prior to enrollment.
- •Severe tricuspid valve stenosis.
- •Need for any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days prior to index procedure.
- •Need for emergent or urgent non cardiac surgery for any reason.
- •Contraindication or known allergy to device components, anticoagulation therapy with a vitamin K antagonist, or to contrast media that cannot be adequately premedicated.
- •History of cardiac transplantation, or participant currently listed for urgent transplant (e.g., UNOS Status 1).
- •Presence of any known life-threatening non-cardiac disease that will limit the subject's life expectancy to less than one year.
- •Contraindication or known hypersensitivity to anticoagulant therapy and/or antiplatelet therapy.
- •Venous anatomy unsuitable for implant delivery.
- •Pacemaker or ICD lead present that would prevent appropriate valve placement.
- •Active COVID-19 infection.
- •Comorbid condition(s) that, in the opinion of the investigator, could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study.
- •Previously enrolled in this study or currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study.
结局指标
主要结局
Rate of procedural success
时间窗: Up to 30 days
Procedural success: freedom from emergency surgery or reintervention related to the device or access procedure, without death, stroke, or device dysfunction
Change in TR from baseline
时间窗: During procedure
Change in TR from baseline: reduction in TR grade immediately following implantation as compared to baseline TR grade, based on TEE imaging.
Rate of device-related serious adverse events
时间窗: Up to 30 days
Rate of device-related serious adverse events, including death (cardiovascular and non- cardiovascular), MI (MVARC definitions), disabling stroke, life-threatening bleeding (MVARC type III-V), renal failure requiring dialysis, emergency surgery, need for additional surgical procedures due to device failure
Rate of technical success
时间窗: During procedure
Technical success: delivery and deployment of the device in the correct position and retrieval of the delivery system.
次要结局
- Clinical performance endpoints - Change in NYHA class(At 30 days, 6 months, 12 months, and then annually)
- Clinical performance endpoints - Change in TR from baseline(At 30 days, 6 months, 12 months)
- Clinical performance endpoints --minute walk test(At 30 days, 6 months and 12 months)
- Quality-of-Life: change from baseline as measured by Kansas City Cardiomyopathy Questionnaire(At 30 days, 6 months and 12 months)
研究者
研究点 (14)
Loading locations...
相似试验
招募中
不适用
Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)Tricuspid Regurgitation FunctionalTricuspid RegurgitationNCT06212193Innoventric LTD15
进行中（未招募）
不适用
TTVR Early Feasibility StudyTricuspid RegurgitationNCT04433065Medtronic Cardiovascular150
终止
不适用
TubeClear® Evaluation in Pediatric Patients (Phase I)Enteral NutritionNCT02724631Children's Hospital of Philadelphia1
招募中
不适用
An Early Feasibility Study of the ReHAB SystemTetraplegiaNCT03898804University Hospitals Cleveland Medical Center12
已完成
不适用
Providing Accessible Diagnostic Evaluations and Psychoeducation for Autism Spectrum Disorder in Rural Southwest VirginiaAutism Spectrum DisorderNCT05822921Virginia Polytechnic Institute and State University21